SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?

BACKGROUND: Metastasis-directed therapy (MDT) significantly delays the initiation of palliative androgen deprivation therapy (pADT) in patients with oligorecurrent prostate cancer (PCa) with a positive impact on patient’s quality of life. However, it remains unclear whether the addition of ADT impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Rans, Kato, Charlien, Berghen, Filip, Ameye, Olivier, De Hertogh, Julie, den Hartog, Céderic, Draulans, Herlinde, Dumez, Benedikt, Engels, Karolien, Goffin, Annouschka, Laenen, Nick, Liefhooghe, Kenneth, Poels, Carl, Salembier, Koen, Slabbaert, Hans, Vandendriessche, Ben, Vanneste, Steven, Joniau, Gert, De Meerleer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743623/
https://www.ncbi.nlm.nih.gov/pubmed/36503429
http://dx.doi.org/10.1186/s12885-022-10374-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743623/
https://www.ncbi.nlm.nih.gov/pubmed/36503429
http://dx.doi.org/10.1186/s12885-022-10374-0

Ejemplares similares